We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 03, 2022

Concurrent Bevacizumab and Re-Irradiation vs Bevacizumab Alone for Treatment of Recurrent Glioblastoma

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
J. Clin. Oncol 2022 Oct 19;[EPub Ahead of Print], CI Tsien, SL Pugh, AP Dicker, JJ Raizer, MM Matuszak, EC Lallana, J Huang, O Algan, N Deb, L Portelance, JL Villano, JT Hamm, KS Oh, AN Ali, MM Kim, SM Lindhorst, MP Mehta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading